Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Chester I agree with this - "My point being that the future potential of Covidity is not dependant on the state of the pandemic" - 100%
Thanks Wildforce
I was musing more about the appetite for shares in companies developing new Coronavirus vaccine as the very thing they are targeting pulls back from the main headlines of the day. Having read the book written by the Oxford Vaccine teams ( Vaxxers ) it is easy to see how everything is judged on the day of the releases and not about the work to that point or the future direction of travel of the Pandemic.
Only a week or two and we will begin to know how Covidity is working.
Chester.
As the Covidity trial continues towards a full phase1 data readout ( May 2022 ) the current Coronavirus pandemic will have began to ebb away, especially as the weather warms. The main success of Covidity will be the clarity of targeting ( non toxic ) and the strength of the 'T' Cell immune response.
If we see impressive results against the Coronavirus Nucleus then the Immunobody Platform will be able to target any Virus of choice. In that scenario it becomes an extremely important / valuable asset going forwards.
My point being that the future potential of Covidity is not dependant on the state of the pandemic when the data is reported it is the strength of the immune responses to the chosen targets.
Chester.
Thanks Burble - it should certainly be an interesting week or two in 'World Scancell'. Hoping for some positive signals in the coming 'Interims' !
I suppose we have no reason to believe that the first Covidity data will be other than good, but the wait is the 'devil itself'. GLA
Violindog
I would say SCIB1 trial validated Immunobody for cancer. It demonstrated that T cells were activated and did what they were told to do.
Covidity will validate if successful the Immunobody platform but this time against infectious disease, it will also validate Avidimab which now has been integrated into it (and therefore validate it for use in potentially any existing or in development antibody therapeutic) AND it will validate the needle free method for administration which then in turn will demonstrate that all three could/should be used against cancer targets.
Pivotal results. But built on many years of knowledge, experience and skilled work by LD et al.
Indeed Chester, the company has gone on record saying that the results will be released late jan / early feb, so either way we don’t have long to wait.
It is also interesting that the ex scancell director has just transferred 590k into his pension in the last couple of days just before the results are due..
Interesting times ahead !
Chester, many thanks.
Hi violindog
Somewhere in the trial docs it did say that blood samples would be taken and anylised and if I remember correctly it was some 6 week after the 2nd dose. So if everything has gone smoothly Scancell will have completed and partially completed blood works from the first 16 ish volunteers.
This is the data we are hoping to be RNS'd by Mid Feb. It is also very possible that they have enough of that data to let us know this week.
What we might hear is, Covidity Well Tolerated, Both Antibodies and 'T' Cells activated against both the Spike and the Nucleocapsid targeted proteins / epitopes.
Hope that helps...
Chester.
Thanks Chester / all, for views.
Fingers crossed for an exciting week ahead.
HAGW.
Chester, can't argue with your analysis. I wonder if Scancell have any data on the first batch of volunteers and if so, could this be released , or would Scancell need to wait until data from all 40.
Guess we may find out next week.
Hi C11, to try and answer part of your question from what we do know.
At the time of the AGM we were told that 16 volunteers had been enrolled so very possible that number had also given their first 'needle free' jab.
The trial had started slowly to ensure the safety of the drug / dose, but by the time of the AGM (which was at the end of November) the enrolment was expected to move forward at a speed of 6 new volunteers per week.
The trial is set for 40 volunteers so 24 still had to be enrolled.
24 divided by 6 = 4 weeks.
Allowing for some slowdown for Christmas and New year if the clinic has moved at that pace it is very likely that all 40 have now had their first dose and the original 16 from the end of November their 2nd.
I know its not a guarantee but very possible that these numbers are where we are at the present time.
Chester.
Chelsea11, impossible to say where we are with recruitment. From your link : 4 DNA trials in phase 3 with one already approved. So SCLP won't be the first in the race but I guess its all about the data and how effective Covidity is. Im not the best at the science so my question is ... will Covidity valadate the whole Immunobody platform ?
It also says last update Oct 14 2021, so clearly not up to date.
As their has been no information made public since the last update, I guess that's all they can say.
Number recruited to trial hasn’t been a topic of conversation on here for a while. Still shows “Recruiting” at the link below but actually, many of the Phase 1 vaccine candidates haven’t even reached that stage after many, many months. I’ll admit I dip-checked but beginning to wonder how accurate the data actually is. Does anyone have a view on this other than we might find out more on 26th?
https://covid19.trackvaccines.org/vaccines/